Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723428 | 0.98 | EPHX2 (0.42) | EPHX2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL17147802 | 0.95 | LMNA (0.36) | EPHX2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL12389039 | 0.91 | PTPN1 (0.34) | EPHX2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL14605257 | 0.77 | EPHX2 (0.36) | EPHX2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL11571042 | 0.76 | EPHX2 (0.37) | EPHX2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL2255757 | 0.74 | HPGD (0.37) | EPHX2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL16968773 | 0.74 | POLB (0.32) | EPHX2ALDH1A1HPGDEPHX1TSHR | |
| SCHEMBL7871029 | 0.72 | EPHX2 (0.35) | EPHX2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL16978486 | 0.72 | NPC1 (0.40) | EPHX2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL23563765 | 0.71 | EPHX2 (0.37) | EPHX2ALDH1A1HPGDRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022131350-A1 | DEOXYRIBONUCLEOSIDE OR DEOXYRIBONUCLEOTIDE HAVING NOVEL ARTIFICIAL BASE CAPABLE OF BEING USED FOR SCREENING FOR DNA APTAMER, AND NUCLEIC ACID CONTAINING SAME | タグシクス・バイオ株式会社 | 2022-06-23 | — | — | WO | disclosed |
| US-9517990-B2 | Negative dielectric anisotropic liquid crystal compounds containing 2,3-difluorophenyl group, and preparation method and use thereof | Shijiazhuang Chenzhi Yonghua Display Materials Co., Ltd. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-9517990-B2 | Negative dielectric anisotropic liquid crystal compounds containing 2,3-difluorophenyl group, and preparation method and use thereof | Shijiazhuang Chenzhi Yonghua Display Materials Co., Ltd. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-9428693-B2 | Liquid crystal composition having negative dielectric anisotropy | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2016-08-30 | — | — | US | disclosed |
| US-9428693-B2 | Liquid crystal composition having negative dielectric anisotropy | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2016-08-30 | — | — | US | disclosed |
| US-9303208-B2 | Liquid crystal compound containing cyclopentyl and difluorometheneoxy linking group, preparation method and application thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-9303208-B2 | Liquid crystal compound containing cyclopentyl and difluorometheneoxy linking group, preparation method and application thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-20150218449-A1 | LIQUID CRYSTAL COMPOUND CONTAINING CYCLOPENTYL AND DIFLUOROMETHENEOXY LINKING GROUP, PREPARATION METHOD AND APPLICATION THEREOF | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATRIALS CO., LTD. (CN) | 2015-08-06 | — | — | US | disclosed |
| US-20150218449-A1 | LIQUID CRYSTAL COMPOUND CONTAINING CYCLOPENTYL AND DIFLUOROMETHENEOXY LINKING GROUP, PREPARATION METHOD AND APPLICATION THEREOF | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATRIALS CO., LTD. (CN) | 2015-08-06 | — | — | US | disclosed |
| US-20150184075-A1 | Liquid Crystal Composition Having Negative Dielectric Anisotropy | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2015-07-02 | — | — | US | disclosed |
| US-20040116431-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-06-17 | — | — | US | disclosed |
| EP-1406609-A2 | SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406609-A4 | SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6706724-B2 | ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETIC AGENT | NITROMED, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | NICOX S.A. (FR) | 2002-08-29 | — | — | US | disclosed |
| WO-2002060378-A2 | SUBSTITUTED ARYL COMPOUNDS AS CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-0691966-B1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX INC (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0691966-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-01-17 | — | — | EP | disclosed |
| CN-1110969-A | Fused phenol derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-11-01 | — | — | CN | disclosed |
| WO-1994022852-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | PTGS2, PTGES2, PTGES | EPHX2 38/4885ALDH1A1 643/4885HPGD 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.